NCT06578546View on ClinicalTrials.gov

Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2026

Conditions
Ph-Positive Acute Lymphoblastic Leukemia
Interventions
DRUG

Venetoclax

100mg d1, 200mg d2, 400mg d2-21, oral (Adjusted according to the plasma concentration of venetoclax on day 4)，every 28 days for a treatment cycle.

DRUG

Azacitidine

75mg/m2 qd, d1-d7, subcutaneous injection, every 28 days for a treatment cycle.

DRUG

Orebatinib

20mg qod, d4-d21, oral, every 28 days for a treatment cycle.

Trial Locations (1)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER